Goldman Sachs analysts added Novonesis (NVZMY) to the firm’s European Conviction List as part of its monthly update. The firm believes there is “significant discovery value” post the merger of Novozymes and Chr Hansen.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVZMY: